Lincomycin, 300 mg/ml 1 ml 10 pcs

Pharmacological action

An antibiotic of the lincosamide group. It has a bacteriostatic effect in therapeutic doses. At higher concentrations it has a bactericidal effect. It inhibits protein synthesis in the microbial cell. It is active mainly against Gram-positive bacteria: aerobic – Staphylococcus spp. (including producing penicillinase); Streptococcus spp. including Streptococcus pneumoniae (except Enterococcus faecalis), Corynebacterium diphtheriae, anaerobic spore-forming bacteria Clostridium spp. Lincomycin is also active against Gram-negative anaerobic bacteria: Bacteroides spp., Mycoplasma spp. Most gram-negative bacteria, fungi, viruses, protozoa are not sensitive to lincomycin. Resistance develops slowly. There is cross-resistance between lincomycin and clindamycin.

After parenteral administration the drug is rapidly distributed in tissues and body fluids, except for cerebrospinal fluid, high concentrations are achieved in bone tissue, bile, urine.

Lincomycin passes through the placenta, penetrates into breast milk.

Protein binding decreases with increasing concentration.

The elimination half-life:

The normal half-life is 5.4 hours (4-6 hours). However, this period may be prolonged in case of liver and/or kidney dysfunction.

The time of reaching maximum plasma concentration:

In intramuscular administration, 0.5 hours;

In intravenous administration, by the end of the infusion.

Extraction: with the kidneys and bile. After intramuscular administration of the drug during 24 hours on the average 10-47% of dose is excreted unchanged in the urine, after intravenous administration – 13-72% of dose. During hemodialysis the drug is not removed from the blood.

Indications

Lincomycin is used in the treatment of septic conditions caused by staphylococci and streptococci, acute and chronic osteomyelitis, pneumonia, purulent infections of the skin and soft tissues, erysipelas, otitis and other infections caused by microorganisms sensitive to this antibiotic, especially infections caused by microorganisms resistant to penicillins and other antibiotics, as well as allergies to penicillins.

Due to the fact that lincomycin accumulates in bone tissue, it is one of the most effective drugs in the treatment of acute and chronic osteomyelitis and other infectious lesions of bones and joints.

Pharmacological effect

Pharmacological action

An antibiotic from the lincosamide group. In therapeutic doses it acts bacteriostatically. At higher concentrations it has a bactericidal effect. Suppresses protein synthesis in microbial cells. Active mainly against gram-positive bacteria: aerobic – Staphylococcus spp. (including those producing penicillinase); Streptococcus spp. incl. Streptococcus pneumoniae (except Enterococcus faecalis), Corynebacterium diphtheriae, anaerobic spore-forming bacteria Clostridium spp. Lincomycin is also active against gram-negative anaerobic bacteria: Bacteroides spp., Mycoplasma spp. Most gram-negative bacteria, fungi, viruses, and protozoa are not sensitive to lincomycin. Resilience is developed slowly. Cross-resistance exists between lincomycin and clindamycin.

After parenteral administration, the drug is quickly distributed in the tissues and fluids of the body, except for the cerebrospinal fluid; high concentrations are achieved in bone tissue, bile, and urine.

Lincomycin passes through the placenta and enters breast milk.

Protein binding decreases with increasing concentration.

Half-life:

The normal half-life is 5.4 hours (4–6 hours). However, this period may be prolonged if liver and/or kidney function is impaired.

Time to reach maximum plasma concentration:

for intramuscular administration – 0.5 hours;

for intravenous administration – towards the end of the infusion.

Excretion: via the kidneys and bile. After intramuscular administration of the drug within 24 hours, on average, 10-47% of the dose is excreted unchanged in the urine, after intravenous administration – 13-72% of the dose. During hemodialysis, the drug is not removed from the blood.

Special instructions

With long-term use of the drug, systematic monitoring of renal and liver function is necessary. Prescription to patients with liver failure is permissible only for health reasons.

If pseudomembranous colitis develops, lincomycin should be discontinued and vancomycin or bacitracin should be prescribed.

To avoid the development of compaction at the injection site and aseptic abscess, it is necessary to administer the drug deeply intramuscularly.

Active ingredient

Lincomycin

Composition

Lincomycin hydrochloride monohydrate in terms of lincomycin base – 300 g.

Excipients:

Disodium salt of ethylenediaminetetraacetic acid (trilon B), sodium hydroxide solution, water for injection up to 1 liter.

Contraindications

Lincomycin hydrochloride is contraindicated in case of hypersensitivity to lincomycin and clindamycin, pregnancy (except in cases where it is necessary for health reasons), if it is necessary to use it during lactation, the issue of stopping breastfeeding should be decided upon, in case of severe liver and kidney diseases (with long courses of treatment, it is necessary to periodically monitor the functions of the liver and kidneys). Parenterally, the drug should not be administered together with peripheral muscle relaxants for myasthenia gravis.

Side Effects

From the digestive system: nausea, vomiting, epigastric pain, diarrhea, glossitis, stomatitis; transient increase in the level of liver transaminases and bilirubin in the blood plasma; with long-term use in high doses, the development of pseudomembranous colitis is possible.

From the hematopoietic system: reversible leukopenia, neutropenia, thrombocytopenia, agranulocytosis, and in rare cases, aplastic anemia and pancytopenia.

Allergic reactions: urticaria, exfoliative dermatitis, Quincke’s edema, anaphylactic shock.

Effects due to chemotherapy: candidiasis.

Local reactions: with intramuscular administration, local irritation, soreness, formation of compaction and sterile abscess are possible. With intravenous administration, thrombophlebitis is possible.

Other: decreased blood pressure, dizziness, weakness (with rapid intravenous administration).

Interaction

When used simultaneously with penicillins, cephalosporins, chloramphenicol or erythromycin, antagonism of the antimicrobial action is possible, and with aminoglycosides – synergism of action.

When used simultaneously with inhalation anesthesia or peripherally acting muscle relaxants, there is an increase in neuromuscular blockade, up to the development of apnea.

Pharmaceutical interactions: lincomycin is incompatible with kanamycin, novobiocin, barbiturates, theophylline, calcium gluconate and magnesium sulfate.

Storage conditions

In a place protected from light, at a temperature of 5–25 °C.

Shelf life

3 years

Manufacturer

Dalkhimfarm, Russia